Antonio C. Wolff
Elite in HER-2 Positive Breast Cancer
Elite in HER-2 Positive Breast Cancer

Overview

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine.

Dr. Wolff is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.

His clinical research consists of co-authoring 268 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of HER-2 Positive Breast Cancer.

Residency
Mount Sinai Hospital, Internal Medicine, 1991
Specialties
Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine, Medical Oncology, 1995
Barnes-Jewish Hospital/Washington University, Hematology and Oncology, 1992
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
French
Portuguese
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Pavilion III STE 1500, Lutherville, MD 21093
Other Locations
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 10th FL, Baltimore, MD 21287

Additional Areas of Focus

Dr. Wolff has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


15 Clinical Trials

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
View 14 Less Clinical Trials
Similar Doctors
Claudine J. Isaacs
Distinguished in HER-2 Positive Breast Cancer
Hematology Oncology | Oncology
Distinguished in HER-2 Positive Breast Cancer
Hematology Oncology | Oncology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (37.2 miles away)
Languages Spoken:
English

Claudine Isaacs is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Isaacs is rated as a Distinguished provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy.

Distinguished in HER-2 Positive Breast Cancer
Hematology Oncology | Hematology | Oncology
Distinguished in HER-2 Positive Breast Cancer
Hematology Oncology | Hematology | Oncology

Virginia Cancer Specialists, P.C.

1860 Town Ctr Dr, Suite 460, 
Reston, VA 
 (47.5 miles away)
Languages Spoken:
English, Hindi, Marathi
Accepting New Patients
Offers Telehealth

Shruti Tiwari is a Hematologist Oncology specialist and a Hematologist in Reston, Virginia. Dr. Tiwari is rated as a Distinguished provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Paget Disease of the Breast, and Intraductal Papilloma. Dr. Tiwari is currently accepting new patients.

Advanced in HER-2 Positive Breast Cancer
Oncology | Hematology | Hematology Oncology
Advanced in HER-2 Positive Breast Cancer
Oncology | Hematology | Hematology Oncology

Maryland Oncology Hematology PA

11886 Healing Way, 
Silver Spring, MD 
 (26.0 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Carol Tweed is an Oncologist and a Hematologist in Silver Spring, Maryland. Dr. Tweed is rated as a Distinguished provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and HER2 Negative Breast Cancer. Dr. Tweed is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wolff's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile